Published in Obesity and Diabetes Week, February 21st, 2005
In connection with the sale of the common stock, the company also will issue warrants to purchase an additional 8,667,247 shares of common stock at an exercise price of $2.00 per share. CytRx has agreed to register all of the privately placed shares of common stock, together with the shares issuable upon exercise of the warrants, for resale.
Rodman & Renshaw served as the lead placement agent in the financing.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.